Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Upstream Bio, Inc. (UPB) Financial Statements

Upstream Bio, Inc. (UPB) reported trailing twelve-month revenue of $3.2M (up 16.0% year on year) and net income of -$156.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$136.5M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

UPBUpstream Bio, Inc.Follow UPB — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
150.1M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
5 Nov, in 12 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Revenue2.42.93.2
Research & development63.0136.8145.8
Operating income-77.8-160.4-170.0
Pre-tax income-62.8-143.4-156.5
Income tax0.00.00.0
Net income-62.8-143.4-156.5
Diluted EPS ($)-5.58-2.66-2.89
Diluted shares (mn)13.753.9—

USD millions · SEC XBRL

Upstream Bio, Inc. — questions

What is Upstream Bio, Inc.'s revenue?
$3.2M over the twelve months to 2026-06-30, up 16.0% year on year, from its 10-Q and 10-K filings.
What is Upstream Bio, Inc.'s net income?
-$156.5M over the twelve months to 2026-06-30.
What is Upstream Bio, Inc.'s free cash flow?
-$136.5M over the twelve months to 2026-06-30.
What are Upstream Bio, Inc.'s diluted earnings per share?
$-2.89 over the twelve months to 2026-06-30.

Every figure on this page comes from Upstream Bio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.